An interventional study of Aerobic exercise intervention and Disease and exercise suggestion in Chronic Obstructive Pulmonary Disease, sponsored by National Cheng Kung University. Recruiting at 1 site in Taiwan. Open to participants aged 30 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-21.
Sponsored by National Cheng Kung University · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 158 studies in Pulmonary Disease, Chronic Obstructive with a site in Taiwan — 28 open to participants now, 30 under way, 6 of them phase 3. Pulmonary Disease, Chronic Obstructive · Taiwan.
Among the 158 studies in Pulmonary Disease, Chronic Obstructive with a site in Taiwan, this one is the 72nd largest by planned enrollment of the 124 interventional ones that give a count, is one of 10 that started in 2024, is one of 51 with no phase, reaches primary completion later than 23 of the 29 other live ones, and was the 135th registered.
5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →28 of the 158 studies in Pulmonary Disease, Chronic Obstructive with a site in Taiwan are open now. Recruiting first, the newest first:
National Yang Ming Chiao Tung University Hospital · Sites in Taiwan
Ages 40–90
Fu Jen Catholic University Hospital · Sites in Taiwan
Ages 40+
Fu Jen Catholic University · Sites in Taiwan
Ages 18+ · Healthy volunteers
Pfizer · Sites in Taiwan, United States, Argentina and 15 more countries
Ages 35–80
AstraZeneca · Sites in Taiwan, Argentina, Egypt and 4 more countries
Ages 18+
A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →
Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.
This study: 30 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
158 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 14 · Phase 3 45 · Phase 4 12
First in 2000; this study’s year is marked. 10 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 90 is above the median of 62 across 3,847 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 139 across the 124 interventional studies, 120 across the 33 observational. Of the 104 that completed or were terminated, 41 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
76 of 158 have an industry lead sponsor. The 10 most frequent:
National Cheng Kung University is the lead sponsor of 64 studies on the registry; 13 are open to participants now.
National Cheng Kung University has 3 studies filed under Pulmonary Disease, Chronic Obstructive — fewer than ten, so there is no comparison to draw.
14 of the studies in Pulmonary Disease, Chronic Obstructive with a site in Taiwan that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05878769Phase 3Hoffmann-La RocheA Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) | 2027-06-30 |
| NCT06491043Meribank Biotech Co., Ltd.Treatment of Chronic Obstructive Pulmonary Disease by Infusion of Allogenic Mesenchymal Stem Cells | 2026-12-30 |
| NCT06851195Kaohsiung Medical University Chung-Ho Memorial HospitalEffect of Neuromuscular Electrical Stimulation of Lower Limbs on Improving Exercise Self-Efficacy, Dyspnea During Activity and Fatigue in Patients With Chronic Obstructive Pulmonary Disease | 2026-12-31 |
| NCT07305649Taipei Veterans General Hospital, TaiwanThe Effectiveness of an Innovative Inhalation Training Device in Improving Medication Accuracy, Dyspnea, and Quality of Life in Elderly Patients With Chronic Obstructive Pulmonary Disease | 2026-12-31 |
| NCT07474220Fu Jen Catholic UniversityExpression of SLC25A48 in Chronic Obstructive Pulmonary Disease | 2026-12-31 |
Add all 14 to your calendar (.ics) → With an account.
Among the 158 studies in Pulmonary Disease, Chronic Obstructive with a site in Taiwan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Investigate the effects of exercise training on the cardiopulmonary function and exercise capacity in COPD patients.
The systemic effects of Chronic Obstructive Pulmonary Disease (COPD) can precipitate a series of complications, including cardiovascular disorders, muscle atrophy, and osteoporosis. These comorbid conditions often result in decreased physical activity and suboptimal physical fitness, compelling patients to lead a sedentary lifestyle to mitigate exercise-induced dyspnea. Addressing the limitations in exercise tolerance remains a critical therapeutic goal in the treatment of COPD. According to research, exercise intolerance is caused by both poor pulmonary function and associated skeletal muscle dysfunction. Blood flow restriction training, a new rehabilitation technique, has shown promise in improving muscular strength at lower exercise intensities and in shorter timeframes, presenting a fresh approach to COPD rehabilitation.
The research aims to investigate the impact of incorporating blood flow restriction training into a holistic aerobic exercise program on exercise capacity and quality of life among patients with COPD. The findings are intended to clarify the potential of this innovative training technique as a supplementary therapeutic strategy in the management of COPD.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The Usual care group will receive COPD and exercise-related education.
Behavioral: Disease and exercise suggestion
The aerobic exercise group will receive cycling training intervention 2-3 times per week for 2 months.
Behavioral: Aerobic exercise intervention
The BFR group will receive cycling training combined with BFR intervention 2-3 times per week for 2 months.
Behavioral: Blood flow restriction (BFR) intervention
The aerobic exercise intervention will utilize an ergometer. The program will be conducted 2-3 times per week over a 3-month period.
The participants will be provided by educational program about COPD self-care and home-based exercise approach.
Blood flow restriction (BFR) intervention will combine aerobic exercise on the ergometer with BFR training. The program will be conducted 2-3 times per week over a 3-month period.
Oxygen consumption (VO2)
Oxygen consumption examined by cardiopulmonary exercise test
Time frame: Change from baseline (0 week) to follow up (20 weeks)
Functional capacity
Functional capacity examined by 6MWT
Time frame: Change from baseline (0 week) to follow up (20 weeks)
Heart Rate Variability
Heart Rate Variability examined by autonomic nervous system
Time frame: Change from baseline (0 week) to follow up (20 weeks)
Pulmonary function test
Pulmonary function test examined by spirometer. Spirometry is a physiological test that measures the ability to inhale and exhale air over time. The main spirometry results are forced vital capacity (FVC), forced expiratory volume in the first second (FEV1), and the FEV1/FVC ratio.
Time frame: Change from baseline (0 week) to follow up (20 weeks)
Maximum respiratory pressure
Maximum respiratory pressure examined by pressure meter
Time frame: Change from baseline (0 week) to follow up (20 weeks)
Quality of life score (COPD-related questionnaire-I)
Quality of life score examined by mMRC Questionnaire.
Time frame: Change from baseline (0 week) to follow up (20 weeks)
Quality of life score (COPD-related questionnaire-II)
COPD Assessment Test (CAT) questionaire
Time frame: Change from baseline (0 week) to follow up (20 weeks)
Quality of life score (COPD-related questionnaire-III)
St George's Respiratory Questionnaire (SGRQ)
Time frame: Change from baseline (0 week) to follow up (20 weeks)
Diaphragm capacity
Diaphragm capacity examined by diaphragmatic ultrasound
Time frame: Change from baseline (0 week) to follow up (20 weeks)
Plan to share: No — IPD sharing plan will be decided after summarized data being published.
Started Nov 2024 (actual). Primary completion is estimated for Dec 2028, 49 months after the start.
Of 1,099 non-industry interventional studies with no phase under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 49 months is above that.
Counting every sponsor, half of 1,187 studies reached it within 22 months; a quarter within 10 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Disease, Chronic Obstructive →
National Cheng Kung University